HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST

Clinical trials for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST explained in plain language.

Never miss a new study

Get alerted when new HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST trials appear

Sign up with your email to follow new studies for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 4 Not yet finished but already full! 1 Completed 1 Terminated 1

New pill tested as potential lifeline for Tough-to-Treat cancers

Disease control Terminated

This early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…

Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST

Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST

Get alerted when new HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST trials appear

New pill tested as potential lifeline for Tough-to-Treat cancers